deltatrials
Terminated PHASE2 INTERVENTIONAL 4-arm NCT01822496

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)

Sponsor: NRG Oncology

Conditions Stage III Non-Small Cell Lung Cancer AJCC v7 Stage IIIA Non-Small Cell Lung Cancer AJCC v7 Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Interventions Carboplatin Cisplatin Crizotinib Erlotinib Etoposide Paclitaxel Radiation Therapy
Updated 20 times since 2017 Last updated: Aug 2, 2019 Started: Nov 4, 2013 Primary completion: Jun 4, 2018 Completion: Jun 4, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from NRG Oncology

See all terminations from NRG Oncology

Other Stage III Non-Small Cell Lung Cancer AJCC v7 trials with similar outcome

Browse all Stage III Non-Small Cell Lung Cancer AJCC v7 trials

Listed as NCT01822496, this PHASE2 trial focuses on Stage III Non-Small Cell Lung Cancer AJCC v7 and Stage IIIA Non-Small Cell Lung Cancer AJCC v7 and remains terminated or withdrawn. Sponsored by NRG Oncology, it has been updated 20 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Apr 2017 · 31 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Nov 2018 · 4 months · monthly snapshot~Nov 2018 – ~Sep 2019 · 10 months · monthly snapshot~Sep 2019 – ~Jan 2021 · 16 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

▶ Show 15 earlier versions

  1. Sep 2019 — Jan 2021 [monthly]

    Terminated PHASE2

  2. Nov 2018 — Sep 2019 [monthly]

    Terminated PHASE2

  3. Jul 2018 — Nov 2018 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  4. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE2

  5. Jan 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE2

  7. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  8. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  9. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

  10. Jun 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

  11. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

  12. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE2

  13. Mar 2017 — Apr 2017 [monthly]

    Recruiting PHASE2

  14. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE2

  15. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NRG Oncology
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Albuquerque, United States , Amarillo, United States , Ames, United States , Anchorage, United States , Anderson, United States , Ann Arbor, United States , Asheville, United States , Atlanta, United States , Augusta, United States and 128 more locations